Navigation Links
Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology

cessful clinical trials of the company's planned products including; the ability to enroll the studies in a timely manner, patient compliance with the study protocol, and a sufficient number of patients completing the studies; the ability of the company to commercialize its planned products; the ability of the company to consummate a favorable marketing agreement with a partner to market EpiCeram(TM); market acceptance of the company's planned products, the company's ability to successfully develop its licensed compounds, alone or in cooperation with others, into commercial products, the ability of the company to successfully prosecute and protect its intellectual property, and the company's ability to hire, manage and retain qualified personnel. The aforementioned factors do not represent an all inclusive list. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained in this press release. In particular, important factors that could cause actual results to differ materially from the company's forward-looking statements include general economic factors, business strategies, the state of capital markets, regulatory conditions, and other factors not currently known to the company, may be significant, now or in the future, and these factors may affect the company to a greater extent than indicated. All forward-looking statements attributable to the company or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in this press release and in other documents that the company files from time to time with the Securities and Exchange Commission including its Annual Report on Form 10-KSB for the year ended December 31, 2006, Quarterly Reports on Form 10-QSB and Current Reports on Form 8-KSB to be filed in 2007. Except as required by law, the company does not undertake any obligation to update any forward-looking statemen
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
2. Ceragenix Announces Results from Phase IV Study of EpiCeram Meet All Primary and Secondary Endpoints
3. Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:10/22/2014)... -- Antigen Discovery Inc. (ADi), a privately held company ... receipt of a National Institutes of Health (NIH) Phase ... of Dental and Craniofacial Research (NIDCR). The one-year $225,000 ... Microarray Chip, which will contain every protein in all ... the development of safe and effective vaccines and therapies ...
(Date:10/22/2014)... 22, 2014  Paper Pak Industries, a manufacturer ... ® Body Guard Bio, a disposable, highly ... bacteria and virus while protecting service providers and ... features a rugged, external nylon shell, watertight zipper, ... leak-proof inner chamber that contains contaminated and potentially ...
(Date:10/22/2014)... , Oct. 22, 2014  With a vision ... health medications, a Global Pharmaceutical and Biotech manufacturer ... technology and turnkey solution to protect their animal ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... was serialized and aggregated by the Xyntek and ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... Ventus Medical, Inc. a privately-held medical device company ... breathing, today announced that it has received CE ... (Photo:   http://photos.prnewswire.com/prnh/20110209/SF45785-b ) ... pleased to accomplish this important regulatory milestone. Receiving ...
... Cempra Pharmaceuticals today announced the appointment of David ... well as announcing an expansion of its clinical ... programs, solithromycin and TAKSTA ... significant anti-infective clinical development experience. Solithromycin ...
Cached Medicine Technology:Ventus Medical Receives CE Mark for Provent® Sleep Apnea Therapy 2Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™ 2Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™ 3
(Date:10/25/2014)... global HCIT outsourcing market is forecast to grow at ... 2018 from $35 billion in 2013. The health insurance ... the HCIT outsourcing market. These industries follow the HCIT ... reduce operational and maintenance costs, increase access to IT ... costs), share risk, and quickly implement new technologies. , ...
(Date:10/25/2014)... October 25, 2014 The ... which verifies IT-accessibility for disabled users by disabled ... logo to Mackin Educational Resources of Burnsville, ... management system and to the Minnesota Alliance for ... "Own Best Medicine" website. Both organizations ...
(Date:10/25/2014)... Mesothelioma researchers are reporting extended survival in ... after his combination drug therapy became too toxic. ... posted on the Surviving Mesothelioma website. , A ... Japan suggests that “maintenance therapy” with pemetrexed may be ... tolerate higher doses of cisplatin. , “Although the ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Researchers who discovered antibiotics ... are cause for concern. The use of ... for human consumption contribute to the development of ... background information from the study. Each year ... 2 million people and kill about 23,000, according ...
(Date:10/22/2014)... At a time when the national ... athletes at all levels, the UPMC Sports Medicine ... discussion where two powerful messages are lost: Concussions can ... in full recoveries every day. , In striving to ... and research, UPMC and the Concussion Program are unveiling ...
Breaking Medicine News(10 mins):Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4
... price hikes in Nepal have irked student organizations who came ... The protestors blocked roads and stoned vehicles and burnt tyres ... commerce minister. The population of Nepal is furious with the ... costlier. ,The student wings of two of the leading ...
... only half of drug- or alcohol-addicted family members seek help ... to 82% of them. ,On interviewing about 902 U.S. ... Drug Addiction poll revealed that a member of their immediate ... ,The findings of the poll were that 51% said their ...
... been affected by bird flu killing thousands of ducks. Health ... infected ducks in from Vietnam. ,Ku Chanthan, a veterinary ... two people were admitted to the hospital on suspicion of ... around 1,300 ducks died from bird flu. Ku added that ...
... Nilambur in Malappuram district of Kerala is all set to ... be Class 4-literate//. Some of the credit would go to ... of that village in the age group 15-50 have not ... , The Kerala State Literacy Mission has organized the ...
... the government health officials, initial clinical trials show that ... ,"Forty-nine healthy people who received the injections ... the vaccine was safe," said Zhang Wei, head of ... Drug Administration (SFDA). ,"The recipients appeared immune ...
... that they say can detect the deadly anthrax in ... they are expensive// and time-consuming. Time is critical because ... ,Professor Peter Seeberger and his team at ... the anthrax surface molecule. They then attached this molecule ...
Cached Medicine News:Health News:Fuel Price Hike Triggers Violent Protests In Nepal 2Health News:Fuel Price Hike Triggers Violent Protests In Nepal 3Health News:Class 4 literacy to be attained by a Kerala village 2Health News:China’s AIDS vaccine-successfully finishes first phas 2
Aire-Cuf® tracheostomy tubes are ideal for short-term to medium-term ventilator support....
... flange tracheostomy tubes are intended ... proper length fixed neck flange ... ,Adjustable neck flange Hyperflex™ ... for both horizontal and vertical ...
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions....
KIMBERLY-CLARK BALLARD Neonatal and Pediatric TRACH CARE Y features lavage/irrigation port and locking thumb port. Multiple French sizes and packaging configurations. Gamma sterilized....
Medicine Products: